What Symptom-Based HRT Prescribing Misses

Hormone replacement therapy for perimenopausal and menopausal women is one of the most debated areas of medicine of the past three decades. The pendulum has swung from widespread prescription in the 1990s to near-abandonment following the 2002 WHI study, and is now swinging back as the limitations of that study and the benefits of body-identical HRT become better understood.

But in the midst of this debate, a more fundamental question is rarely asked: what does this individual woman’s hormonal picture actually look like before we prescribe? And after we prescribe, how do we know the hormones are being metabolised safely and effectively? Symptom-based prescribing — which remains the norm in UK practice — answers neither question. The DUTCH Plus test does.

The Oestrogen Metabolism Problem Nobody Is Checking

Oestrogen is not a single entity. It is metabolised through three pathways after use: the 2-OH pathway (protective, antiproliferative), the 4-OH pathway (genotoxic, associated with DNA damage and breast cancer risk), and the 16-OH pathway (proliferative, associated with oestrogen-sensitive tissue stimulation). The ratio of these pathways matters enormously for long-term safety of oestrogen use — whether endogenous or exogenous via HRT.

The 2-OH pathway requires adequate methylation to convert 2-hydroxyoestrone to the safe 2-methoxyoestrone (2-MeOE1). Methylation, in turn, requires MTHFR-adequate folate metabolism, B12, B6, and SAMe availability. A woman with MTHFR variants who cannot effectively methylate her oestrogens accumulates 2-OH and 4-OH metabolites rather than converting them safely. This is measurable on DUTCH as low 2-MeOE1 and elevated 4-OH relative to 2-OH.

Prescribing oestrogen to a woman with poor methylation capacity without first identifying and correcting the methylation deficit is prescribing oestrogen into a system that cannot detoxify it safely. This is not a rare edge case — MTHFR variants affect approximately 40-60% of the population.

The Progesterone Measurement Problem

Serum progesterone is an unreliable marker for transdermal progesterone supplementation. Progesterone applied transdermally bypasses first-pass hepatic metabolism and enters tissues directly — particularly adipose tissue and red blood cells — without appearing reliably in serum. A woman using transdermal progesterone cream may have low serum progesterone despite adequate tissue levels, or may have adequate serum levels that do not reflect tissue exposure.

DUTCH dried urine testing detects progesterone metabolites (pregnanediol) that reflect tissue progesterone exposure regardless of administration route. This is why DUTCH is the appropriate monitoring tool for transdermal progesterone — and why serum testing underestimates progesterone status in women using this route.

The Cortisol Context

Perimenopausal symptoms — sleep disruption, hot flushes, anxiety, cognitive fog, mood instability, fatigue — overlap substantially with symptoms of HPA axis dysregulation and high or dysregulated cortisol. Starting HRT without knowing the cortisol pattern means treating oestrogen and progesterone deficiency while potentially missing a dominant cortisol component that HRT will not address.

DUTCH shows the full cortisol diurnal curve, the cortisol awakening response (CAR), total cortisol production via metabolised cortisol, and the DHEA-S level that contextualises whether the adrenal system has reserve. A woman with a flat CAR, low metabolised cortisol, and absent DHEA response is a different clinical picture from one with high free cortisol and disrupted diurnal curve — even when oestrogen levels are identical.

Prescribing hormones without knowing the hormonal landscape is like painting a room without knowing what colour it already is. DUTCH shows the canvas. Then we can talk about what to add and how much.